Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:44 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Study of Dalotuzumab + MK-2206, Dalotuzumab + MK-0752, and Dalotuzumab + Ridaforolimus Combination Therapies in Participants With Advanced Cancer (MK-0646-027)
NCT01243762 · Merck Sharp & Dohme LLC · PHASE1 · terminated · last registry update 2018-08-16 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “The study was terminated for business reasons and not due to any safety or efficacy concerns related to dalotuzumab.” | – | Registry record, Merck Sharp & Dohme LLC |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against IGF1R within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2019-07-11Results posted on the registry: Bristol-Myers Squibb, BMS-754807 + letrozole (NCT01225172)
- 2019-07-09Results posted on the registry: Cedars-Sinai Medical Center, a drug against IGF1R (NCT00915954)
- 2019-06-03Results posted on the registry: University of Oxford, Linsitinib (NCT02546544)
- 2019-03-25Results posted on the registry: Merck Sharp & Dohme LLC, Ridaforolimus + Dalotuzumab (NCT01605396)
- 2019-03-20Results posted on the registry: M.D. Anderson Cancer Center, MK-0646 + Gemcitabine (NCT00769483)
- 2018-10-09Results posted on the registry: Merck Sharp & Dohme LLC, dalotuzumab (NCT00635778)
- 2018-09-13Also stopped (terminated): Novartis Pharmaceuticals, BYL719 + AMG 479 (NCT01708161)
- 2018-09-13Results posted on the registry: University Health Network, Toronto, ASP7487, Velcade, Dexamethasone (NCT01672736)
- 2018-09-13Also stopped (terminated): University Health Network, Toronto, ASP7487, Velcade, Dexamethasone (NCT01672736)
- 2018-08-27Also stopped (terminated): Merck Sharp & Dohme LLC, Temozolomide + Vincristine (NCT00960063)
- 2018-08-24Also stopped (terminated): Merck Sharp & Dohme LLC, Carboplatin + Epirubicin (NCT00954512)
- 2018-08-23Also stopped (terminated): Merck Sharp & Dohme LLC, robatumumab (NCT00617890)
- 2018-06-28Results posted on the registry: Novartis Pharmaceuticals, BYL719 + AMG 479 (NCT01708161)
- 2018-03-26Results posted on the registry: Boston Children's Hospital, Recombinant Human Insulin Growth Factor 1 (rhIGF-1) + Placebo (NCT01777542)
- 2018-03-09Phase 3 first posted: Amgen, Teprotumumab (NCT03461211)
- 2018-03-02Results posted on the registry: Nationwide Children's Hospital, rhIGF (Increlex) (NCT00764699)
- 2018-03-02Also stopped (terminated): Nationwide Children's Hospital, rhIGF (Increlex) (NCT00764699)
- 2017-12-27Results posted on the registry: Dana-Farber Cancer Institute, AMG 479 (NCT01024387)
- 2017-11-21Also stopped (terminated): Emory University, Sorafenib and OSI-906 (NCT01334710)
- 2017-10-02Phase 3 first posted: Amgen, Teprotumumab (NCT03298867)
- 2017-09-05Also stopped (terminated): Merrimack Pharmaceuticals, MM-151 + MM-121 (NCT02538627)
- 2017-08-30Results posted on the registry: Amgen, teprotumumab + normal saline (NCT01868997)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision